Trials / Completed
CompletedNCT05618496
Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Contipro Pharma a.s. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the trial is to confirm safety of a new product - Epipad. The main impact of the device is to provide good environment for the healing of chronic wounds and wounds in the last healing phase (granulation and epithelisation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Sodium Hyaluronate Lyophilizate | Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression. |
Timeline
- Start date
- 2022-10-26
- Primary completion
- 2023-10-31
- Completion
- 2023-10-31
- First posted
- 2022-11-16
- Last updated
- 2024-02-08
Locations
4 sites across 1 country: Czechia
Source: ClinicalTrials.gov record NCT05618496. Inclusion in this directory is not an endorsement.